{"id":"NCT01185704","sponsor":"Merck KGaA, Darmstadt, Germany","briefTitle":"Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)","officialTitle":"A Phase IIIb Randomized Open-label Study to Compare the Estradiol Level on the Releasing Day in Two Regimen of Cetrotide® 0.25 mg Used From Day 1 or From Day 7 of the Menstrual Cycle (Day 0 or Day 6 of Stimulation) in Polycystic Ovarian (PCO) Women in ART (IVF/ICSI).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11","primaryCompletion":"2011-10","completion":"2012-02","firstPosted":"2010-08-20","resultsPosted":"2013-07-03","lastUpdate":"2014-02-13"},"enrollment":136,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Polycystic Ovarian Syndrome"],"interventions":[{"type":"DRUG","name":"Cetrorelix acetate","otherNames":["Cetrotide®"]},{"type":"DRUG","name":"Cetrorelix acetate","otherNames":["Cetrotide®"]},{"type":"DRUG","name":"Recombinant Human Choriogonadotropin (r-hCG)","otherNames":["Ovitrelle®"]},{"type":"DRUG","name":"Recombinant human follicle stimulating hormone (r-hFSH)","otherNames":[]}],"arms":[{"label":"Day 1 protocol","type":"EXPERIMENTAL"},{"label":"Day 7 protocol","type":"EXPERIMENTAL"}],"summary":"This is a randomized open-label study to compare between in-vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes of the two regimen of Cetrotide® (Cetrorelix acetate) which are 0.25 milligram (mg) used from Day 1 or Day 7 of the menstrual cycle (Day 0 or Day 6 of stimulation) in polycystic ovarian (PCO) women in assisted reproductive technology (ART).","primaryOutcome":{"measure":"Estradiol (E2) Levels on r-hCG Day","timeFrame":"r-hCG day (end of stimulation cycle [approximately 15 days])","effectByArm":[{"arm":"Day 1 Protocol","deltaMin":1668.86,"sd":862.62},{"arm":"Day 7 Protocol","deltaMin":1672.8,"sd":835.49}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":16},"locations":{"siteCount":1,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":65},"commonTop":["Headache","Pelvic pain","Ovarian Hyperstimulation syndrome","Nausea","Injection site erythema"]}}